English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe NCCN Oncology Research Program (ORP) announces funding of a project that will underpin innovative research on optimal management of side effects secondary to treatment with poly ADP ribose polymerase inhibitors (PARPi).
Tag: prostate cancer
Fighting prostate cancer, from farm to table, at MSU
With a nod to bringing local, fresh ingredients directly to our dinner plates, Michigan State University researchers will soon be applying their own farm-to-table approach to the fight against prostate cancer. From therapeutic ingredient production to research and testing — it’s all happening at MSU.
MRI-guided radiation therapy reduces long-term side effects for patients with prostate cancer
After a comprehensive two-year follow-up, researchers at the UCLA Health Jonsson Comprehensive Cancer Center found that MRI-guided stereotactic body radiotherapy (SBRT) for prostate cancer significantly reduced long-term side effects and improved quality of life, particularly in bowel and sexual health, compared to conventional CT-guided treatment.
Researchers report first published case of a patient with treatment-emergent neuroendocrine prostate cancer who showed a remarkable response to an anti-HER2 antibody-drug conjugate
A new case report published in Annals of Internal Medicine describes the success of human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate trastuzumab deruxtecan (T-DXd) in a patient with HER2-expressing treatment-emergent neuroendocrine prostate cancer (t-NEPC).
First of a Kind Case Study Shows Remarkable Improvements for Prostate Cancer Patient
Researchers from the George Washington University and the Washington DC Veterans Affairs Medical Center have published a landmark case report that signifies a potential breakthrough in the treatment… …
Novel Prostate Cancer Treatment Increases Overall Survival Rates for Late-Stage Prostate Cancer Patients
A global study of a combination drug therapy, led by an investigator at Huntsman Cancer Institute, has shown improved overall survival rates for metastatic prostate cancer compared to standard treatments.
New Advances in Prostate Cancer Diagnosis: Outcomes from the 2022 Panjiayuan Consensus Conference
The 2022 Panjiayuan Consensus Conference, held by the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, has introduced pivotal advancements in prostate targeted biopsy (TB) strategies and development, marking a significant leap forward in the diagnosis and management of prostate cancer (PCa).
UCLA efforts to provide prostate cancer treatment in the community gets $6 million boost
The UCLA Urology department has been awarded $6 million from the California Department of Health Care Services to continue providing vital care and critical services to underinsured and uninsured Californians diagnosed with prostate cancer.
Sarasota Memorial Research Institute Participates in Groundbreaking Prostate Cancer Imaging Study
Prostate cancer is the most common non-skin cancer in men in the US, and the 4th most common tumor diagnosed worldwide. As part of its commitment to improving the diagnosis and staging of this disease, Sarasota Memorial Research Institute is proud to announce its participation in the Solar-Stage study sponsored by Curium.
Study Suggests a Healthy Diet May Help Keep Low Grade Prostate Cancer from Progressing to More Dangerous States During Active Surveillance
In a peer-reviewed study believed to be the first of its kind published, a research team led by Johns Hopkins Medicine provides scientific evidence that a healthy diet may reduce the chance of low risk prostate cancer progressing to a more aggressive state in men undergoing active surveillance — a clinical option in which men with lower risk cancer are carefully monitored for progression in lieu of treatments that could have undesired side effects or complications.
International Collaboration Addresses Rising Cancer Rates in South America
NCCN announces a renewed collaboration with LACOG to publish new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer: Brazil Edition. Additional Brazilian adaptations of NCCN Guidelines for other cancer types are planned for the future.
Research points to potential new treatment for aggressive prostate cancer subtype
In two new papers, both published in Cell Reports Medicine, researchers from the University of Michigan Rogel Cancer Center describe the mechanisms of how alterations in the CDK12 gene drive prostate cancer development and report on a promising degrader that targets CDK12 and a related gene to destroy tumors.
Case Western Reserve, Vanderbilt universities to develop incisionless prostate surgery using MRI and robotics
Researchers at Case Western Reserve University and Vanderbilt University are pioneering a new approach to prostate cancer surgery by combining advanced robotics and “low-field” MRI technology.
Case Western Reserve, Vanderbilt universities to develop incisionless prostate surgery using MRI and robotics
Researchers at Case Western Reserve University and Vanderbilt University are pioneering a new approach to prostate cancer surgery by combining advanced robotics and “low-field” MRI technology.
IMRT and proton therapy offer equally high quality of life and tumor control for people with prostate cancer
People with low- and intermediate-risk prostate cancer treated with either of two types of contemporary radiation therapy — proton beam therapy or intensity modulated radiation therapy (IMRT) — achieved equally high rates of tumor control with no differences in patient-reported quality of life, according to a first-of-its-kind phase III clinical trial comparing the two technologies. Findings of the PARTIQoL trial will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
Additional research highlights from the 2024 ASTRO Annual Meeting
In addition to the studies featured on the press program (details here) for the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting, the following studies were recommended by ASTRO experts and may be of interest to journalists.
ASTRO Presidential Symposium Presentation Will Focus on Leading-Edge Microboost Technology for Prostate Cancer
Microboost technology — a leading-edge approach to targeted radiation treatment for prostate cancer — will be the topic of Dr. Brandon Mahal’s Presidential Symposium presentation next week at the American Society for Radiation Oncology (ASTRO) meeting.
Nearly 200 People Show Up for Their Health
Hackensack Meridian Health’s Men’s Health Day Offers Screenings for Those at High Risk for Prostate Cancer & Other Diseases
Ceevra 3D Models Improve Outcomes for Patients Undergoing Prostate Cancer Surgery
In a multisite randomized controlled trial published in JAMA Network Open in September 2024, the use of Ceevra 3D models in robotic prostatectomy procedures were shown to reduce risk of cancer recurrence, improve functional outcomes, and improve rates of trifecta outcomes.
New AI Tool by Mount Sinai Researchers Could Reshape Prostate Cancer Care
Researchers at the Icahn School of Medicine at Mount Sinai have developed an advanced artificial intelligence (AI)-driven tool to improve the management and prognosis of prostate cancer. Details on the findings were reported in the September 20 online issue of European Urology [https://doi.org/10.1016/j.eururo.2024.07.013].
New law regulating out-of-pocket drug spending saves cancer patients more than $7,000 a year, study finds
As prescription oral chemotherapies have become a common form of cancer treatment, some patients were paying more than $10,000 a year for medications. A new study finds that efforts to cap prescription drug spending are yielding significant out-of-pocket savings for these patients.
PATERSON MAN RECEIVES LIFE SAVING SCREENING AT FREE HACKENSACK MERIDIAN HEALTH EVENT
When 64 year old Jerome Simmons came across an ad on social media for Hackensack Meridian Health’s Annual Men’s Health Event, he almost ignored it. But something in his gut told him to stop scrolling and read more. A health…
Researchers identify factor that drives prostate cancer-causing genes
Researchers at the University of Michigan Health Rogel Cancer Center have uncovered a key reason why a typically normal protein goes awry and fuels cancer. They found the protein NSD2 alters the function of the androgen receptor, an important regulator of normal prostate development.
UC San Diego Health Experts Available to Discuss Prostate Cancer and Urology Awareness Month
September is Prostate Cancer and Urology Awareness Month, and UC San Diego Health experts are available to share the latest in symptoms, screening recommendations, early detection and treatment options. UC San Diego Health offers the most advanced prostate cancer treatments,…
Radiation oncology research and clinical trial results to be featured at ASTRO’s Annual Meeting in Washington
The American Society for Radiation Oncology (ASTRO) announced today the seven studies to be highlighted in the 2024 ASTRO Annual Meeting press program. Researchers will discuss their findings in news briefings held September 30 and October 1 at the Walter E. Washington Convention Center in Washington, D.C. and via live webcast.
National Cleveland Clinic Survey Examines Generational Divide in Men’s Health
National Cleveland Clinic Survey Examines Generational Divide in Men’s Health
Precision Drug Olaparib May Be Effective Without Hormone Therapy for Some Men with Biochemically Recurrent Prostate Cancer
The anti-cancer drug olaparib may be effective in treating biochemically recurrent prostate cancer without accompanying hormone therapy for men who have mutations in genes such as BRCA2, according to results of a phase II clinical trial of 51 patients conducted at the Johns Hopkins Kimmel Cancer Center and three other sites.
Mount Sinai Researchers Discover Novel Nanoparticles in Blood With Potential to Transform Cancer Diagnosis
Scientists at the Icahn School of Medicine at Mount Sinai have identified a new class of RNAs packed into tiny particles known as extracellular vesicles (EVs) that could revolutionize how cancer and other diseases are diagnosed. The team found that these molecules undergo changes when cancer is present, suggesting their potential as biomarkers for detecting prostate cancer or as targets for therapy.
From flat to overflowing: adding another dimension to tissue analysis
A team of NIBIB-funded researchers recently developed an AI platform that can analyze 3D pathology images to predict disease outcomes. Their method had improved performance in predicting prostate cancer outcomes when compared with traditional pathology approaches, such as analysis by expert pathologists using 2D images.
Study suggests an MRI may help doctors predict more aggressive prostate cancer in patients
New Corewell Health™ research suggests an MRI scan can help predict whether patients with intermediate-risk prostate cancer (cancer confined to the entire prostate) may have more aggressive cancer in five years.
Dr. Gopal Gupta Awarded on Newsweek America’s Best Prostate Cancer Surgeons 2024 List
MAYWOOD, IL – Newsweek and Statista are proud to announce that Gopal Gupta, MD affiliated with Loyola Medicine has earned a position in the America’s Best Prostate Cancer Surgeons 2024 list. This is an exclusive list of only 150 doctors in the country. Congratulations on this achievement! In an era of informed decision-making, it is increasingly important for patients to make well-founded choices about which doctor to consult for their specific condition.
Upfront mental health supports for men with prostate cancer
Mental health screenings must be incorporated in routine prostate cancer diagnoses say University of South Australia researchers. The call follows new research that shows men need more supports both during and immediately after a diagnosis of prostate cancer.
MSK Research Highlights, July 31, 2024
New research from Memorial Sloan Kettering Cancer Center (MSK) showed giving chemotherapy shortly after a stem cell or bone marrow transplant from a less than perfectly matched donor greatly reduces the chances that the patient will develop graft-versus-host disease (GVHD); and sheds new light on cell state changes in prostate cancer.
Dr. Tanya Stoyanova receives $1.8 million to reveal new treatment strategies for advanced prostate cancer
Dr. Tanya Stoyanova, associate professor of molecular and medical pharmacology and urology at the David Geffen School of Medicine at UCLA(Link is external) (Link opens in new window), was awarded a $1.8 million grant from the National Cancer Institute to identify new drivers and test new therapeutic strategies for advanced treatment-resistant prostate cancer.
Radiation oncologists awarded $1.8 million grant to advance personalized cancer therapy
The funding helps further the team’s work in improving the quality of life for men diagnosed with prostate cancer by predicting and preventing significant long-term side effects from radiation treatment.
The Harvey L. Neiman Health Policy Institute Launches Cancer Equity Compass
The Harvey L. Neiman Health Policy Institute announces the public launch of a new online tool that reveals the overlap between cancer disparities and social determinants of health (SDOH) using advanced heat maps of U.S. counties. The Cancer Equity Compass can identify high-opportunity targets for policies and programs to achieve equitable health outcomes in underserved populations.
Screening for prostate cancer with first-line MRI less cost-effective than first-line PSA testing
A cost-effectiveness analysis found that screening for prostate cancer using biparametric magnetic resonance imaging (bpMRI) as a first-line approach is less cost-effective than first-line prostate-specific antigen (PSA) testing with second-line multiparametric MRI (mpMRI).
ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1/2 study.
For this presentation at ASCO 2024, please email the media contact for more information.
ASCO: Large precision oncology study identifies differences in prostate cancer genomics among a racially and ethnically diverse cohort of U.S. veterans
A new study(Link is external) (Link opens in new window) led by a UCLA-VA collaborative team looking at the landscape of genomic alterations in more than 5,000 veterans with metastatic prostate cancer uncovered differences in the genomic makeup of cancer cells that were associated with race and ethnicity.
Drug Helps Reprogram Macrophage Immune Cells, Suppress Prostate and Bladder Tumor Growth
A novel therapy that reprograms immune cells to promote antitumor activity helped shrink hard-to-treat prostate and bladder cancers in mice, according to research from the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy and Johns Hopkins Drug Discovery.
Metastatic Prostate Cancer Research: PSMAfore follow-on study favors radioligand therapy over change to androgen receptor pathway inhibition
Follow-on analysis of results from the phase 3 PSMAfore study, along with the overall study results, support the consideration of 177Lu-PSMA-617 as a new standard treatment approach for this prevalent population of patients with mCRPC. Research led by Dana-Farber Cancer Institute and others.
Tip Sheet: Funding awarded to two ovarian cancer research projects, progress towards liquid biopsies for lung cancer — and cannabis and alcohol use in patients
Below are summaries of recent Fred Hutch Cancer Center research findings, patient stories and other news.
Cedars-Sinai Experts Available for Interviews at American Urological Association Annual Meeting May 3-6
Physician-scientists from the Department of Urology at Cedars-Sinai will be attending the American Urological Association (AUA) Annual Meeting May 3-6 in San Antonio, Texas, and are available to discuss the latest research and innovations in urological care.
MD Anderson Research Highlights for April 24, 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
New urine-based test detects high-grade prostate cancer, helping men avoid unnecessary biopsies
Researchers at the University of Michigan Rogel Cancer Center have developed a new urine-based test that addresses a major problem in prostate cancer: how to separate the slow-growing form of the disease unlikely to cause harm from more aggressive cancer that needs immediate treatment.
Moffitt Treats First Clinical Trial Patient with Gamma Delta CAR T for Bone Metastatic Prostate Cancer
Moffitt Cancer Center has treated its first patient in an investigator-initiated, phase 1 clinical trial investigating the safety and efficacy of a chimeric antigen receptor T-cell (CAR T) therapy for prostate cancer that has metastasized to the bone.
Analysis Group Researchers Identify Racial Disparities in Treatment of Metastatic Castration-Sensitive Prostate Cancer
Researchers from Analysis Group, a global leader in health economics and outcomes research (HEOR), have coauthored the first large-scale study that revealed racial disparities in treatment, survival, and access to care among patients with metastatic castration-sensitive prostate cancer (mCSPC) since the first novel hormonal therapy was approved in 2018.
Smart nanoprobe illuminates prostate cancer cells
NIBIB-supported researchers have developed a smart nanoprobe designed to infiltrate prostate tumors and send back a signal using an optical imaging technique known as Raman spectroscopy.
Black Men Have Greater Microvascular Dysfunction than White Men after Prostate Cancer Diagnosis
Microvascular function is lower in Black men following a recent diagnosis of prostate cancer, compared to white men.
Sylvester Physician Co-Authors Global Plan to Combat Prostate Cancer
Annual prostate cancer cases worldwide are projected to double by the year 2040, and annual deaths are projected to increase by 85% – mainly among men in low- and middle-income countries. A commissioned report in The Lancet seeks to guide cancer experts worldwide on how to manage this massive influx of prostate cancer patients.